Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

VEGFA elevation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

VEGFA elevation	Gastric Cancer	VEGFA elevation	Gastric Cancer	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B
VEGFA elevation	Hepatocellular Cancer	VEGFA elevation	Hepatocellular Cancer	lenvatinib Resistant: B - Late Trials lenvatinib Resistant : B	lenvatinib Resistant: B - Late Trials lenvatinib Resistant : B
VEGFA elevation	Ovarian Cancer	VEGFA elevation	Ovarian Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
VEGFA elevation	Hepatocellular Cancer	VEGFA elevation	Hepatocellular Cancer	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
VEGFA elevation	Glioblastoma	VEGFA elevation	Glioblastoma	pembrolizumab + bevacizumab Resistant: C3 – Early Trials pembrolizumab + bevacizumab Resistant : C3	pembrolizumab + bevacizumab Resistant: C3 – Early Trials pembrolizumab + bevacizumab Resistant : C3
VEGFA elevation	Renal Cell Carcinoma	VEGFA elevation	Renal Cell Carcinoma	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3
VEGFA elevation	Hepatocellular Cancer	VEGFA elevation	Hepatocellular Cancer	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3
VEGFA elevation	Clear Cell Renal Cell Carcinoma	VEGFA elevation	Clear Cell Renal Cell Carcinoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
VEGFA elevation	Renal Cell Carcinoma	VEGFA elevation	Renal Cell Carcinoma	bevacizumab + atezolizumab Resistant: C3 – Early Trials bevacizumab + atezolizumab Resistant : C3	bevacizumab + atezolizumab Resistant: C3 – Early Trials bevacizumab + atezolizumab Resistant : C3